Harsch Mutya's most recent trade in VYNE Therapeutics Inc was a trade of 3,581 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. | 30 Jun 2025 | 3,581 | 133,065 (0%) | 0% | 1.7 | 5,909 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Grant, award, or other acquisition of securities at price $ 0.81 per share. | 02 Jun 2025 | 1,145 | 136,646 (0%) | 0% | 0.8 | 927 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.58 per share. | 31 Mar 2025 | 8,828 | 135,501 (0%) | 0% | 1.6 | 13,948 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Harsch Mutya | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.35 per share. | 31 Dec 2024 | 4,697 | 144,329 (0%) | 0% | 3.4 | 15,735 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 30 Sep 2024 | 105 | 149,026 (0%) | 0% | 1.9 | 197 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 01 Jul 2024 | 143 | 149,131 (0%) | 0% | 1.9 | 275 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 01 Apr 2024 | 161 | 149,274 (0%) | 0% | 3.1 | 496 | Common Stock |
| VYNE Therapeutics Inc | Harsch Mutya | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Harsch Mutya | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 62,500 | 149,596 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Harsch Mutya | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.28 per share. | 01 Jan 2024 | 161 | 149,435 (0%) | 0% | 2.3 | 367 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 62,500 | 87,096 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 30 Jun 2023 | 157 | 25,750 (0%) | 0% | 4.1 | 644 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 3.46 per share. | 31 May 2023 | 3,664 | 25,907 (0%) | 0% | 3.5 | 12,664 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 31 Mar 2023 | 478 | 22,243 (0%) | 0% | 3.1 | 1,472 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 20 Mar 2023 | 10,000 | 22,721 (0%) | 0% | 2.5 | 25,000 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.15 per share. | 31 Dec 2022 | 1,813 | 229,144 (0%) | 0% | 0.2 | 272 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.22 per share. | 30 Sep 2022 | 1,813 | 230,957 (0%) | 0% | 0.2 | 404 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 30 Jun 2022 | 1,813 | 232,770 (0%) | 0% | 0.4 | 705 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. | 31 Mar 2022 | 3,630 | 234,583 (0%) | 0% | 0.7 | 2,360 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 75,000 | 75,000 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 75,000 | 238,213 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 30 Sep 2021 | 1,484 | 164,697 (0%) | 0% | 1.4 | 2,063 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 60,860 | 60,860 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 60,859 | 166,181 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 30 Jun 2021 | 3,551 | 105,322 (0%) | 0% | 3.5 | 12,464 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. | 31 Mar 2021 | 1,765 | 108,873 (0%) | 0% | 6.8 | 12,073 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 68,162 | 68,162 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 29,213 | 110,638 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Grant, award, or other acquisition of securities at price $ 1.45 per share. | 30 Nov 2020 | 10,460 | 327,525 (1%) | 0% | 1.4 | 15,115 | Common Stock |
| VYNE Therapeutics Inc | Mutya Harsch | Chief Legal Officer and GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 30 Sep 2020 | 1,822 | 317,065 (1%) | 0% | 1.7 | 3,025 | Common Stock |